Discontinued Hepatitis Agent: Clevudine
M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson in Kucers’ The Use of Antibiotics, 2017
In earlier editions of this text, this chapter included a number of clinical trials, the results of which were published between 2004 and 2007. These clinical trials showed that clevudine had activity toward hepatitis B virus, but the studies apparently downplayed or missed some of the drug’s side effects and relatively poor efficacy compared with other drugs.
Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
Published in Expert Opinion on Pharmacotherapy, 2019
Hans L. Tillmann, Gbeminiyi Samuel
Another L-nucleoside pyrimidine analog, Clevudine, was found to have potent antiviral activity against HBV. 30 mg clevudine daily resulted in a cumulative rate of undetectable HBV DNA of 67–83%. Clevudine use though approved in Korea and the Philippines is limited in others because of myopathy [3,12]. Given its side effect and the many alternative antivirals available, clevudine has not been recommended by any guideline that we are aware of and cannot see a place for it. Its mutation profile also include the ‘YMDD’ motif.
Related Knowledge Centers
- Adefovir
- Hepatitis B
- Nucleoside Analogue